2024
Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapy
2016
Identifying cost‐effective dynamic policies to control epidemics
Yaesoubi R, Cohen T. Identifying cost‐effective dynamic policies to control epidemics. Statistics In Medicine 2016, 35: 5189-5209. PMID: 27449759, PMCID: PMC5096998, DOI: 10.1002/sim.7047.Peer-Reviewed Original ResearchConceptsNet health benefitHighest net health benefitHealth benefitsTransmission-reducing interventionsDynamic policiesNovel viral pathogensCurrent interventionsHealth policyMathematical decision modelViral pathogensMonetary outcomesPolicy makersInterventionPolicyDecision modelStatic policyEpidemicEpidemic dataVaccinationVaccinePerformance measures